159 related articles for article (PubMed ID: 20622834)
1. Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India.
Padmanabhan S; Amin T; Sampat B; Cook-Deegan R; Chandrasekharan S
Nat Biotechnol; 2010 Jul; 28(7):671-8. PubMed ID: 20622834
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
Lee VJ; Tay SK; Teoh YL; Tok MY
BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
[TBL] [Abstract][Full Text] [Related]
3. Does India need an indigenous HPV vaccine and why?
Bharati K; Ganguly NK
J Public Health Policy; 2013 May; 34(2):272-87. PubMed ID: 23447031
[TBL] [Abstract][Full Text] [Related]
4. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers.
Chandrasekharan S; Amin T; Kim J; Furrer E; Matterson AC; Schwalbe N; Nguyen A
Vaccine; 2015 Nov; 33(46):6366-70. PubMed ID: 26368398
[TBL] [Abstract][Full Text] [Related]
5. Worldwide impact of the human papillomavirus vaccine.
Hakim AA; Dinh TA
Curr Treat Options Oncol; 2009 Apr; 10(1-2):44-53. PubMed ID: 19387841
[TBL] [Abstract][Full Text] [Related]
6. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.
Jit M; Chapman R; Hughes O; Choi YH
BMJ; 2011 Sep; 343():d5775. PubMed ID: 21951758
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
Cleemput I; Thiry N
Pharmacoeconomics; 2009; 27(5):433; author reply 433-4. PubMed ID: 19586082
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
9. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
Kiatpongsan S; Kim JJ
PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.
Jiang Y; Ni W; Wu J
BMJ Open; 2019 Nov; 9(11):e031186. PubMed ID: 31767588
[TBL] [Abstract][Full Text] [Related]
11. HPV vaccine strategies: the cost of HPV and the choice of vaccine.
Morris SR
Sex Transm Infect; 2009 Sep; 85(5):315-6. PubMed ID: 19773455
[No Abstract] [Full Text] [Related]
12. Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.
Insinga RP; Dasbach EJ; Allen SE; Carides GW; Myers ER
Value Health; 2008 Dec; 11(7):1022-32. PubMed ID: 18489503
[TBL] [Abstract][Full Text] [Related]
13. [Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways].
Crager SE
Rev Panam Salud Publica; 2015 Jan; 37(1):59-68. PubMed ID: 25791189
[TBL] [Abstract][Full Text] [Related]
14. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
15. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
[TBL] [Abstract][Full Text] [Related]
16. Comparing bivalent and quadrivalent HPV vaccines.
Verheijen RH
BMJ; 2011 Sep; 343():d5720. PubMed ID: 21951757
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
Annemans L; Rémy V; Oyee J; Largeron N
Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
19. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
Capri S; Gasparini R; Panatto D; Demarteau N
Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
[TBL] [Abstract][Full Text] [Related]
20. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
Crager SE; Guillen E; Price M
Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
